Medical Disclaimer
This website is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, changing, or stopping any medication or supplement. Dosage information reflects published FDA-approved labeling or publicly available clinical trial data — individual treatment decisions must be made by a licensed physician.
About retatrutide
Retatrutide (LY3437943) is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. It is not yet FDA-approved but has shown remarkable efficacy in Phase 2 clinical trials. This page summarizes publicly available clinical trial dosing information — it is not a prescription guide.
Indication
Investigational. Not FDA-approved. Clinical trial data only. Do not use this information to self-medicate.
Research / Trial Dosing Reference
Dosing data from published clinical trials. Not an approved prescription protocol.
| Week / Phase | Dose | At 2.5 mg/mL | At 5 mg/mL | Notes |
|---|---|---|---|---|
| Weeks 1–4 (trial initiation) | 1 mg | 2 units (5 mg/mL) | 1 units (10 mg/mL) | Initiation dose in Phase 2 trial. Investigational — not approved for clinical use. |
| Weeks 5–8 (trial escalation) | 2 mg | 4 units (5 mg/mL) | 2 units (10 mg/mL) | Dose escalation step in trial protocol. |
| Weeks 9–12 | 4 mg | 8 units (5 mg/mL) | 4 units (10 mg/mL) | Low maintenance arm in Phase 2 study. |
| Maintenance arm (8 mg) | 8 mg | 16 units (5 mg/mL) | 8 units (10 mg/mL) | Middle maintenance arm. Associated with ~17.5% body weight loss at 24 weeks. |
| Maintenance arm (12 mg) | 12 mg | 24 units (5 mg/mL) | 12 units (10 mg/mL) | Highest trial arm. Associated with ~24% body weight loss at 48 weeks. Do not use without physician supervision. |
Units shown assume a standard U-100 insulin syringe (100 units = 1 mL). Always confirm your vial concentration with your pharmacy.
Dose Calculator
Enter your prescribed dose and vial concentration to calculate how many units to draw.
mg ↔ Units Dose Calculator
Convert between milligrams and insulin-syringe units for compounded GLP-1 medications. Uses a standard U-100 syringe (100 units = 1 mL).
2.5 mg at 2.5 mg/mL → 1.000 mL → 100 units on a U-100 (100-unit / 1 mL) insulin syringe
Always verify calculations with your prescribing provider or pharmacist before administering any medication. This calculator is for reference only.
Injection Sites
Abdomen (trial protocol)
Subcutaneous injection into abdominal fatty tissue.
- Same technique as other GLP-1 injections
- Rotate sites
Storage Instructions
- Investigational product — storage handled by clinical trial site
- If compounded: follow pharmacy instructions
- Typically requires refrigeration
Common Side Effects
Contact your healthcare provider if side effects are severe or persistent.
- Nausea (most common in trials)
- Vomiting
- Diarrhea
- Constipation
- Decreased appetite
- GI side effects generally similar to other GLP-1 agonists
Frequently Asked Questions
Is retatrutide FDA-approved?
How does retatrutide compare to tirzepatide?
Can I get retatrutide from a compounding pharmacy?
When will retatrutide be available?
Primary Source
FDA / Clinical Source
Dosing information sourced from: https://clinicaltrials.gov/study/NCT04867785
Related Guides
Cagrilintide Dosage Chart
CagriSema (combination with semaglutide — investigational)
Cagrilintide dosage — amylin analogue overview
BPC-157 Dosage Chart
Research peptide — not FDA-approved
BPC-157 dosage reference — research peptide guide
NAD+ Injection Dosage Chart
Various — compounded
NAD+ injection dosage guide — IV and subcutaneous reference